Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

L.A. McKeown

June 05, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

Could an App Replace Statin Prescribing by Doctors?

Michael O'Riordan

September 08, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Shelley Wood

January 18, 2016

Advertisement

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Could an App Replace Statin Prescribing by Doctors?

Roughly 80% of ESC Guideline Writers Have Financial COIs

FDA Approves Icosapent Ethyl for Reducing CVD Events

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content